FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 
 
 
For period ending 17 October 2018
 
GlaxoSmithKline plc
(Name of registrant)
 
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 
 
Form 20-F x     Form 40-F
 
--
 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
 
Yes      No x
 
 
 
 
GlaxoSmithKline plc (the 'Company')
 
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
 
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of thefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
 
 
 
 
 
 
b)
Nature of thetransaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.516
 
208
 
£14.516
 
226
 
£14.516
 
792
 
£14.516
 
207
 
£14.516
 
226
 
d)
Aggregatedinformation
Aggregated volumePrice
 
 
 
 
1659
£14.516
 
 
 
e)
Date of thetransaction
2018-10-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 

 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R G Connor
b)
Position/status
President, Global Vaccines
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of thefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
 
 
 
 
 
 
b)
Nature of thetransaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.516
 
141
 
£14.516
 
117
 
£14.516
 
167
 
£14.516
 
117
 
d)
Aggregatedinformation
Aggregated volumePrice
 
 
 
 
543
£14.516
 
 
 
e)
Date of thetransaction
2018-10-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S Dingemans
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of thefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
 
 
 
 
 
 
b)
Nature of thetransaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.516
 
274
 
£14.516
 
205
 
£14.516
 
560
 
£14.516
 
274
 
£14.516
 
205
 
d)
Aggregatedinformation
Aggregated volumePrice
 
 
 
 
1518
£14.516
 
 
 
e)
Date of thetransaction
2018-10-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of thefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
 
 
 
 
 
 
b)
Nature of thetransaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.516
 
101
 
£14.516
 
74
 
£14.516
 
88
 
£14.516
 
101
 
£14.516
 
74
 
d)
Aggregatedinformation
Aggregated volumePrice
 
 
 
 
438
£14.516
 
 
 
e)
Date of thetransaction
2018-10-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position/status
CEO, GSK Consumer Healthcare
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of thefinancial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053 
 
 
 
 
 
 
 
b)
Nature of thetransaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 October 2018 on ADSs held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$38.47
 
84
 
$38.47
 
82
 
d)
Aggregatedinformation
Aggregated volumePrice
 
 
 
 
166
$38.47
 
 
 
e)
Date of thetransaction
2018-10-12
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr L Miels
b)
Position/status
President, Global Pharmaceuticals
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of thefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
 
 
 
 
 
 
b)
Nature of thetransaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.516
 
159
 
d)
Aggregatedinformation
Aggregated volumePrice
n/a (single transaction)
 
 
e)
Date of thetransaction
2018-10-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D S Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of thefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
 
 
 
 
 
 
b)
Nature of thetransaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.516
 
129
 
£14.516
 
93
 
£14.516
 
162
 
£14.516
 
93
 
£14.516
 
129
 
d)
Aggregatedinformation
Aggregated volumePrice
 
 
 
 
606
£14.516
 
 
 
e)
Date of thetransaction
2018-10-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms K Terrell
b)
Position/status
Chief Digital & Technology Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of thefinancial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
 
 
 
 
 
 
 
b)
Nature of thetransaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 October 2018 on ADSs held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
$38.47
 
28
 
d)
Aggregatedinformation
Aggregated volumePrice
n/a (single transaction)
e)
Date of thetransaction
2018-10-12
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
SVP, Human Resources
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of thefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
 
 
 
 
 
 
b)
Nature of thetransaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.516
 
189
 
£14.516
 
141
 
£14.516
 
177
 
£14.516
 
189
 
£14.516
 
141
 
d)
Aggregatedinformation
Aggregated volumePrice
 
 
 
 
837
£14.516
 
 
 
e)
Date of thetransaction
2018-10-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P C Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of thefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
 
 
 
 
 
 
b)
Nature of thetransaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£14.516
 
115
 
£14.516
 
88
 
£14.516
 
110
 
d)
Aggregatedinformation
Aggregated volumePrice
 
 
 
 
313
£14.516
 
 
 
e)
Date of thetransaction
2018-10-12
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
 
 
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: October 17, 2018 
 
 
 
 
By: VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc